The company's breakthrough puts the market one step closer to having an injection-free alternative for the treatment of ...

Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...

Eli Lilly (LLY) stock surges after releasing promising test results from the company's GLP-1 pill, which would serve as an alternative to injectable weight-loss drugs. Novo Nordisk (NVO) and Hims & ...

HIMS has experienced similar dramatic drops before. During the 2022 inflation surge, the stock fell 87%, and in 2020, it ...

Patients who received Lilly’s pill did not show signs of liver damage, the company said. Liver side effects scuttled Pfizer’s ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

Trial data data showed Lilly's experimental weight-loss pill worked as well as the Ozempic shot, bringing it one step closer ...

Pharma advertisers have kicked off 2025 with a bang, with the top 10 spenders throwing almost 30% more money behind their TV ...

Teladoc stock has declined significantly, from a high of $14 per share in February to $7 per share. Read why I downgrade TDOC ...